

TIGLUTIK (riluzole, oral suspension)

Diagnosis Considered for Coverage:

- Amyotrophic lateral sclerosis (ALS)

Coverage Criteria:

For diagnosis listed above:

- Medical rationale why patient is unable to use riluzole tablet, **and**
- Dose does not exceed FDA label maximum.

Coverage Duration: Length of Benefit

Effective: 12/01/2018GF